Atrandi, a Lithuanian biosciences firm, has raised a $25 million Series A funding round led by Lux Capital, amongst other investors.

The funds will be used to drive the advancement of Single-Cell Multiomics with Semi-Permeable Capsule Technology, as well as aiding in scientific breakthroughs via research programmes. Atrandi’s scientific platform currently enables more than 200 research labs globally and has supported discoveries and resulting products in the field of eukaryotic and microbial genomics. This funding round will also assist the company in expanding into the U.S. biosciences market by increasing its customer base, including the opening of an office in Boston in 2025.